Skip to main content
Premium Trial:

Request an Annual Quote

Tasigna 'Discontinued'

Premium

Novartis is stopping the development of its drug Tasigna — which was being developed as an initial therapy for patients with gastrointestinal stromal tumors — because it's unlikely that the drug will help patients live longer than those on the current standard of care, Gleevec, report The Wall Street Journal's Anita Greil. An independent data-monitoring committee recommended the discontinuation after comparing Tasigna and Gleevec in a late-stage study, the company said. Novartis had hoped to be able to replace Gleevec with Tasigna when Gleevec goes off-patent in a few years, Greil adds.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.